SCHEMBL18033077

SCHEMBL18033077

C=COc1ccc(C(=O)OC)cc1OCCO[Si](C)(C)C(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.38
▸ MDH1 P40925 1/20 0.37
▸ MDH2 P40926 1/20 0.37
▸ TTR P02766 1/20 0.36
▸ L3MBTL1 Q9Y468 2/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ RAB9A P51151 2/20 0.35
▸ KMT2A Q03164 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ ALOX15 P16050 1/20 0.35
▸ SMPD1 P17405 3/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ NOTUM Q6P988 2/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ HDAC3 O15379 1/20 0.34
▸ TUBB4A P04350 1/20 0.34
▸ TUBB P07437 1/20 0.34
▸ TUBA3C P0DPH7 1/20 0.34
▸ HDAC4 P56524 1/20 0.34
▸ TUBA1B P68363 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18054821 0.82 CA12 (0.47) MAPTMDH1MDH2TTRL3MBTL1
SCHEMBL1665370 0.81 S1PR4 (0.47) MAPTRAB9AKMT2AKDM4EMEN1
SCHEMBL26814603 0.81 CYP1A2 (0.44) MAPTMDH1MDH2TTRL3MBTL1
SCHEMBL18033090 0.81 PDE4D (0.41) MAPTMDH1MDH2
SCHEMBL20976373 0.81 MAPT (0.42) MAPTMDH1MDH2TTRL3MBTL1
SCHEMBL18031237 0.81 PDE4D (0.46) MAPTKDM4ESMPD1SMN1; SMN2CYP1A2
SCHEMBL18033365 0.81 SMPD1 (0.50) MAPTRAB9AKMT2AKDM4ESMPD1
SCHEMBL25314479 0.80 MRGPRX4 (0.47) MAPTL3MBTL1KMT2AKDM4EMEN1
SCHEMBL20976380 0.80 RAB9A (0.42) MAPTTTRL3MBTL1TDP1RAB9A
SCHEMBL25312796 0.79 ALDH1A1 (0.48) MAPTRAB9AKDM4ECYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10358453-B2 Antiviral compounds ALIOS BIOPHARMA, INC. (US) 2019-07-23 — — US disclosed
WO-2016138158-A1 ANTIVIRAL COMPOUNDS ALIOS BIOPHARMA, INC. (US) 2016-09-01 — — WO disclosed
US-20160244460-A1 ANTIVIRAL COMPOUNDS Janssen Pharmaceuticals, Inc. 2016-08-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10358453-B2 Antiviral compounds MAVS, SARS1, ZC3HAV1 MAPT 4665/4885MDH1 625/4885MDH2 1261/4885
US-20160244460-A1 ANTIVIRAL COMPOUNDS MAVS, SARS1, ZC3HAV1 MAPT 4665/4885MDH1 625/4885MDH2 1261/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback